Rick Bright, “one of the nation’s leading vaccine development experts and the director of the Biomedical Advanced Research and Development Authority, is no longer leading the organization, officials told STAT.”
“The shakeup at the agency, known as BARDA, couldn’t come at a more inopportune time for the office, which invests in drugs, devices, and other technologies that help address infectious disease outbreaks and which has been at the center of the government’s coronavirus pandemic response.”
“Bright, whose departure was confirmed by three industry sources and two current Trump administration sources, will instead move into a narrower role at the National Institutes of Health. Gary Disbrow, Bright’s former deputy at BARDA, will serve as the acting director of the office, an HHS spokesperson confirmed to STAT…”
Source: HHS replaces director charged with COVID-19 vaccines and drug development – By Nicholas Florko, April 21, 2020. STAT
G2X TAKE: With all that HHS is challenged with, it is worth noting that changes are afoot at the Agency as this longtime HHS ASPR leader and Director of the HHS ASPR Biomedical Advanced Research and Development Authority (BARDA) is taking on a new challenge with NIH.
A couple other significant moves to note include:
One longtime National Disaster Medical System leader and SME has recently re-joined the Agency as an advisor to HHS supporting the HHS ASPR Emergency Management and Medical Operations (EMMO) division and to support the development of strategies to optimize the
Additional intel for members only. Please login or click join today for more details.